TNF-beta Inhibitors & Biosimilars
1 drugsAbout TNF-beta
Tumor Necrosis Factor-beta (TNF-beta), also known as lymphotoxin-alpha (LT-α), is a cytokine that mediates communication between cells, particularly within the immune system. It plays a crucial role in lymphoid organ development and in regulating immune responses.
TNF-beta's involvement in inflammatory pathways makes it a relevant target for therapeutic intervention. Currently, there is no genetic evidence data available linking TNF-beta to specific diseases in this dataset.
TNF-beta is targeted by one FDA-approved drug, ENBREL, a fusion protein developed by IMMUNEX. ENBREL has 6 indications and was first approved in 1998.
Top TNF-beta Drugs
IMMUNEX is the only company with an approved drug targeting TNF-beta.
The market is highly concentrated, indicating potential entry barriers or limited commercial opportunity.
TNF-beta Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets TNF-beta, using fusion protein modality.
Explore alternative modalities like antibodies or small molecules to differentiate from existing therapies.
TNF-beta Clinical Trials 140 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on TNF-beta. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 24 | 17 | 6 | 1 | 74% |
| Phase 2 | 20 | 13 | 3 | 4 | 81% |
| Phase 3 | 41 | 35 | 3 | 3 | 92% |
| Phase 4 | 55 | 36 | 15 | 4 | 71% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
TNF-beta Drug Approval Timeline (1998 - 1998)
The first and only drug, ENBREL, was approved in 1998.
The approval timeline suggests market saturation; consider novel approaches to revitalize the target.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 77 (26 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on TNF-beta. A trial counts if an approved drug acting on TNF-beta is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.